CBG vs CBN

CBG: Mechanism mapped in vitro, plus one small human trial in our registry Low
CBN: Active in lab assays. Its headline sleep claim has been tested in people, and those trials missed their pre-specified endpoints Not supported

From the evidence status row of the table below.

Walk the gummy aisle and the pairing writes itself: CBG for the day, CBN for the night. The chemistry puts them at opposite ends of the plant's life. CBG (cannabigerol) is the "mother" cannabinoid, the neutral form of CBGA. CBN (cannabinol) is what THC oxidises into as cannabis ages, and it sells widely as a sleep aid, a use the evidence has not established. Neither is meaningfully intoxicating: CBG not at all, CBN mildly at most.

The day-and-night story is tidy marketing, and the research is less obliging. CBN's sleep claim has already been tested in people, and the trials missed their pre-specified endpoints. CBG's record holds lab-bench pharmacology, one small human trial in our registry, and a placebo-controlled veterans' sleep study, still in intake review (Emerson 2025), that found no improvement in sleep quality over placebo.

The grades, strongest first. Three things are verified and graded as fact: each compound's chemical identity, how it forms, and CBG's laboratory (in-vitro) receptor pharmacology. Claims about effects or benefits, CBN's "sleep" reputation above all, belong to whoever makes them, so they appear as theirs ("marketed as…," "some users report…") with their limits beside them. The scale runs the six-rung evidence ladder; an empty record reads "catalogue in progress." Not medical or legal advice.

At a glance

	CBG	CBN
Full name	CBGCannabigerol	CBNCannabinol
Formula / CAS	CBGC₂₁H₃₂O₂ · CAS 25654-31-3 · PubChem CID 5315659	CBNC₂₁H₂₆O₂ · CAS 521-35-7 · PubChem CID 2543
Intoxicating?	CBGNo. Non-intoxicating Established	CBNNon-intoxicating, or weakly intoxicating at most; still debated Low
General legal status (2026, US)	CBGGenerally federally legal when hemp-derived (≤0.3% delta-9 THC), under the 2018 Farm Bill; state rules vary and are still changing; informational, not legal advice	CBNCovered by the same federal hemp rules, though CBN can cross-react with THC drug tests; state rules vary and are still changing; informational, not legal advice
Commonly marketed for (attributed)	CBGMarketed for everyday calm, focus, gut comfort and skin. These are third-party claims and are not established	CBNMarketed as a sleep aid, and some users report drowsiness; controlled human studies have not established the effect
Evidence status (graded)	CBGMechanism mapped in vitro, plus one small human trial in our registry Low	CBNActive in lab assays. Its headline sleep claim has been tested in people, and those trials missed their pre-specified endpoints Not supported

The six rungs, and the words each one permits

grade: Established: Settled science — replicated human data, or biochemistry that is not in dispute. “is shown to”
grade: Demonstrated: Shown reproducibly in controlled experiments — typically laboratory (in-vitro) work. “has been shown to”
grade: Emerging: An early signal — preclinical (animal) work, or human evidence too limited to settle the question. “may · early evidence suggests”
grade: Low: Limited and low-confidence — sparse, indirect, or single-source data. “limited evidence · unclear”
grade: Hypothesized: Proposed and plausible — but not yet shown. “proposed mechanism”
grade: Not supported: Tested, and the evidence does NOT support it. This is a finding against the claim — not an absence of evidence. “evidence does not support”
Catalogue in progress: Not a rung: our registry holds nothing graded on the question yet. Absence is not evidence against.

A grade rates the support for a claim across the literature, never a single study. How we grade evidence.

Figure P · targets side by side

CBG and CBN at six targets: what our registry records, and where it records nothing

How to read a cell: An oxblood ring holds the direction: a bar: blocks; a chevron: activates; a chevron with a bar: activates, then desensitises; two bars: damps activation. A gold ring with a dot: recorded in a review, direction qualified by the source, no rung of its own. A dashed frame: no graded interaction in our registry.
CB1 cannabinoid receptor: CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro Cascio 2010. CBN: no graded interaction in our registry.
CB2 cannabinoid receptor: CBG: no graded interaction in our registry. CBN: no graded interaction in our registry.
α2-adrenoceptor: CBG: activates (agonist; drawn as a chevron), in vitro grade: Demonstrated study type: In vitro Cascio 2010. CBN: no graded interaction in our registry.
5-HT1A serotonin receptor: CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro Cascio 2010. CBN: no graded interaction in our registry.
TRPV1 and TRPV2 ion channels: CBG: activates, then desensitises (agonist, then desensitiser; drawn as a chevron with a bar), in vitro grade: Demonstrated study type: In vitro De Petrocellis 2011. CBN: no graded interaction in our registry.
TRPM8 ion channel: CBG: blocks (antagonist; drawn as a bar), in vitro grade: Demonstrated study type: In vitro De Petrocellis 2011. CBN: no graded interaction in our registry.

An oxblood frame is a registry record measured in receptors, cells or tissue, which is what in vitro means, with the direction as a glyph: a bar blocks, a chevron activates, a chevron with a bar activates and then desensitises, two bars damp activation. A dashed frame means the registry holds no graded interaction there, which is not the same as evidence of none. None of this is an effect in people, and none of it is a dose. CBN has no receptor-level record in our registry at any of the six targets: the registry is CBG-centred, and the empty column says so. Sources: Cascio 2010, De Petrocellis 2011. CBG's record at researcher depth is on the monograph's target map; the receptors themselves are drawn on the ECS map →

What's actually established

Start with what the two share: neither is meaningfully intoxicating, and even CBN's weak effect at most is debated Established · / Low. Past that, the citable pharmacology belongs to CBG. In vitro, Cascio 2010 found it acts as an α2-adrenoceptor agonist, a 5-HT1A antagonist and a CB1 antagonist, and De Petrocellis 2011 showed that it modulates TRP channels. CBN's most important entries in the record are trial results, and they cut against the label: controlled human studies have not established the headline "sleep" benefit.

CBG identity & origin Established: CBG is the neutral, decarboxylated form of CBGA, the "mother cannabinoid" where the plant's cannabinoid biosynthesis starts.
CBN identity & origin Established: C₂₁H₂₆O₂, CAS 521-35-7, PubChem CID 2543. CBN is an aromatic product of THC's oxidative breakdown and builds up as cannabis ages under oxygen, heat and light, which makes rising CBN in stored flower or extract a sign that the THC is ageing.
CBG receptor pharmacology Demonstrated · in vitro: agonist at the α2-adrenoceptor and antagonist at 5-HT1A and CB1 (Cascio 2010); desensitiser at TRPV1/TRPV2 and antagonist at TRPM8 (De Petrocellis 2011). Blood-pressure caution: because CBG acts on α2-adrenoceptors, which help regulate blood pressure, consult a clinician if you take cardiovascular medication.
CBG preclinical signals Emerging: Borrelli 2013 reported reduced inflammation in a mouse model of colitis, and Appendino 2008 found antibacterial activity in vitro, MRSA included. Both results are preclinical, and neither is established in humans.
CBN "sleep" Not supported: CBN is sold widely as "the sleep cannabinoid," and some users report drowsiness. When the claim was tested in people, the trials missed the endpoints they had pre-specified (Bonn-Miller 2024; Lavender 2026). The reputation likely reflects terpenes in aged cannabis rather than CBN itself. A tested negative, then, and a sleep claim on a CBN label now runs against the trial record.
CBN drug-test caution Established: CBN's chemical kinship with THC lets it cross-react with the THC immunoassays used in standard screening, and CBN products may contain trace THC. Two routes, one outcome: a real risk of a positive result.
A known gap for CBG No primary evidence: our registry holds no primary study of CBG and intraocular pressure in either direction, so a claim that CBG lowers eye pressure or treats glaucoma has nothing behind it. The record is empty here, which is different from a finding against.
Head-to-head [catalogue in progress]: no controlled human trial has compared CBG and CBN directly, on any outcome.

Common questions

What's the difference between CBG and CBN?

CBG is where the plant's cannabinoid chemistry starts, and CBN is where THC ends up as it ages. CBG is the neutral form of CBGA, the compound the plant builds its other cannabinoids from; CBN is what THC turns into as it oxidises over time. The two are chemically distinct, they hit different lab targets, and neither is meaningfully intoxicating (CBN weakly at most). Established

Is CBG or CBN better for sleep?

Neither, on current evidence, and both have now been tested. Trials of CBN in people missed their pre-specified sleep endpoints (Bonn-Miller 2024; Lavender 2026). A placebo-controlled trial of CBG in veterans found no improvement in sleep quality over placebo (Emerson 2025, in intake review). No trial has compared the two directly. For both compounds, the sleep marketing has got well ahead of the data. (not medical advice) Not supported

Do CBG and CBN get you high?

No; neither produces THC's high. CBG is non-intoxicating, and in lab studies it blocks the CB1 receptor (Cascio 2010), the opposite of what THC does there. CBN is the more curious case. It forms from THC yet leaves THC's intoxication behind: it is non-intoxicating or weakly intoxicating at most, with only weak activity at cannabinoid receptors. Established

Is CBG better for daytime and CBN for nighttime?

The split is a marketing convention, and the science has not established it. CBG is often sold as a daytime "focus" cannabinoid and CBN as a nighttime "sleep" one, yet controlled human studies support neither role. CBG has a single small effect trial in our registry, plus a veterans' sleep trial (Emerson 2025, in intake review) that found no improvement over placebo, and CBN's sedative reputation has already come up short in testing. A buyer learns more from product quality than from a time of day printed on the label. (not medical advice) Low

Will CBG or CBN fail a drug test?

CBN is the bigger risk. Its chemical kinship with THC means it can cross-react with THC immunoassays, and CBN products may carry trace THC. CBG sits outside what the test targets, although full-spectrum CBG can carry trace THC too. Isolates reduce the risk, and a promise that any product is test-safe is one no seller can keep. Established

Are CBG and CBN legal?

In the US, hemp-derived CBG and CBN (≤0.3% delta-9 THC) are generally federally legal under the 2018 Farm Bill as of 2026. Below the federal line the picture blurs: state laws vary and keep changing, and shifting "total-THC" readings add uncertainty. Outside the US, novel-food and cannabis rules differ again. Informational, not legal advice; check the rules where you sell or buy. Established

Informational only — not our claims, and not advice. The statements on this page about potential effects, benefits, or uses reflect claims made by third parties (manufacturers, media, traditional use, or preliminary research) and are presented for educational and informational purposes only. CBG Atlas does not make, adopt, endorse, or affirm these claims, and does not represent them as fact. These statements have not been evaluated by the Food and Drug Administration (or any regulator) and are not intended to diagnose, treat, cure, or prevent any disease. Nothing here is medical, legal, or professional advice; cannabinoid effects, safety, and legal status vary by person, product, and jurisdiction and can change over time. Consult a qualified professional before making any health or purchasing decision. Where we can, we show how strong the evidence is and cite the source; where evidence is thin or absent, we say so. Peregrine Biopharma funds the platform and holds no editorial authority.

Report a safety event: if you experienced a possible adverse effect from a cannabinoid product, please report it via the platform's "Report a safety event" path.

Verified anchors: Cascio 2010 (PMID 20002104) · De Petrocellis 2011 (PMID 21175579) · Borrelli 2013 (PMID 23415610) · Appendino 2008.

Before you act on what you have read

Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.

Each grade rates the support for a claim across the literature. It does not rate any single study. An effect in cells may never show up in people. The grades cover the studies checked up to 9 August 2026. This page is for information and is not medical advice.

Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.

Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.

Report a safety event →

Keep exploring

The compounds compared

More comparisons

All comparisons

Reference